Yarrow Bioscience, Inc.: 5%+ holders

Yarrow Bioscience, Inc. has 20 Schedule 13D or 13G filings on record since 2025-08-14. 10 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

AI Biotechnology LLC

The disclosure in Item 4 is hereby amended and supplemented by adding the following at the end thereof: On July 27, 2026, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, as amended by Amendment No. 1 thereto on January 30, 2026, by and among VYNE Therapeutics Inc., Yellow Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of VYNE Therapeutics Inc., and Yarrow Bioscience, Inc., a Delaware corporation ("Pre-Merger Yarrow"), Yellow Merger Sub Corp. merged with and into Pre-Merger Yarrow, with Pre-Merger Yarrow continuing as a wholly owned subsidiary of VYNE Therapeutics Inc. and the surviving corporation of the merger (the "Merger"). In connection with the completion of the Merger, VYNE Therapeutics Inc. changed its name to Yarrow Bioscience, Inc. Prior to the consummation of the Merger, the Issuer effected a 1-for-50 reverse stock split of its Common Stock by filing a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became legally effective on July 24, 2026 (the "Reverse Stock Split"). Upon the effectiveness of the Reverse Stock Split, every 50 shares of Common Stock issued and outstanding immediately prior thereto were automatically and without further action on the part of the Issuer or any holders of Common Stock combined into one share of Common Stock. No fractional shares were issued as a result of the Reverse …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-29; the filing has the rest

Orbimed Advisors LLC

This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-05; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes